Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Viela Bio

Explore full profile

Clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases

Gaithersburg, United StatesFounded 2018Biotech & Life Sciences
Valuation $3.05B Market cap · 2021
Revenue $12M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Viela Bio

Viela Bio is focused on developing and commercializing innovative medicines aimed at treating a broad spectrum of autoimmune and severe inflammatory diseases. The company employs a unique approach that targets the underlying molecular causes of these diseases, enabling the development of more precise therapies. This method also helps in identifying patients who are more likely to respond to the treatments and allows for the pursuit of multiple indications for each product candidate. Viela Bio serves patients suffering from autoimmune and severe inflammatory conditions, operating primarily in the biopharmaceutical market. The business model revolves around the research, development, and commercialization of novel therapeutic solutions. Revenue is generated through the sale of these specialized medicines, as well as potential partnerships and licensing agreements with other pharmaceutical companies. Viela Bio's clinical pipeline is robust, with multiple candidates in various stages of development, aimed at addressing unmet medical needs in the autoimmune and inflammatory disease space.

Source: Dealroom company data

At a glance

Founded
2018
Headquarters
Gaithersburg, United States
Listing
IPO 2019
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

Series B and later1 investor entered at this stage

  • MedImmune
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States83.3%
🇮🇳 India16.7%
2 countries shown

Patents

Estimated portfolio value
$49M

28 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Viela Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Viela Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.